Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended October 1, 2000, for PerkinElmer, Inc. (Note: The request metadata lists "REVVITY, INC.", but the filing text identifies the registrant as PerkinElmer, Inc., which later became Revvity). The company operates in four segments: Life Sciences, Optoelectronics, Instruments, and Fluid Sciences. The reporting period includes significant M&A activity, specifically the acquisition of NEN Life Sciences, Inc. in July 2000 and Vivid Technologies, Inc. in January 2000.
Key Financial Metrics
| Metric | Three Months Ended Oct 1, 2000 | Nine Months Ended Oct 1, 2000 |
|---|---|---|
| Sales (Continuing Ops) | $431.9 million | $1,232.9 million |
| Operating Income | $30.7 million | $118.1 million |
| Net Income | $2.1 million | $53.9 million |
| Diluted EPS (Net Income) | $0.04 | $1.06 |
| Cash from Operations | N/A | $83.3 million |
| Cash & Equivalents | $132.9 million | $132.9 million (Ending Balance) |
| Short-Term Debt | $294.8 million | $294.8 million (Ending Balance) |
| Long-Term Debt | $579.3 million | $579.3 million (Ending Balance) |
Margins: Operating margin for continuing operations was 7.1% for the quarter and 9.6% for the nine-month period. Net income margin was 0.5% for the quarter and 4.4% for the nine-month period.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 11% year-over-year for the quarter and 32% for the nine-month period. Organic growth was 12% for the quarter, driven by strength across all segments.
- Profitability: Operating income improved significantly from a loss of $0.3 million in Q3 1999 to $30.7 million in Q3 2000. This turnaround was driven by revenue growth and productivity initiatives, despite significant acquisition-related charges.
- Acquisition Charges: The period included substantial non-cash charges related to acquisitions:
- In-Process R&D: $24.3 million (NEN) and $8.1 million (Vivid) expensed.
- Inventory Revaluation: $0.9 million (NEN) and $1.1 million (Vivid).
- Debt Structure: Long-term debt increased significantly due to the issuance of $460 million in zero-coupon senior convertible debentures in August 2000 to refinance commercial paper used for the NEN acquisition.
Guidance, Outlook, and Risks
Management Commentary: Management attributes the operating profit increase to strong revenue growth, productivity initiatives, and the divestiture of unprofitable businesses. Operating profit before nonrecurring items was $54.4 million for the quarter, a 74% increase year-over-year.
Restructuring: The company expects to incur approximately $7 to $10 million in cash outlays for restructuring plans through the remainder of fiscal 2000, with the majority of actions expected in 2001.
Risks and Contingencies:
- Market Risk: Exposure to foreign exchange rates (primarily Euro, Yen, British Pound) and interest rate fluctuations. The company uses derivative instruments to hedge these risks.
- Acquisition Integration: Risks associated with integrating NEN and Vivid, including integration costs and the realization of synergies.
- Accounting Changes: Adoption of SFAS No. 133 (Derivatives) and SAB No. 101 (Revenue Recognition) is expected to have limited material impact, though revenue recognition policies are being reviewed.
Investor Verification Checklist
- Acquisition Impact: Verify the pro forma financial impact of the NEN and Vivid acquisitions, specifically the $24.3 million in-process R&D charge and its effect on future R&D capitalization.
- Debt Obligations: Review the terms of the $460 million convertible debentures, noting the $921 million repayment obligation at maturity in 2020 and the conversion price of ~$85/share.
- Restructuring Accruals: Confirm the $46.0 million accrued restructuring costs related to acquisitions and the timeline for cash outlays in 2001.
- Discontinued Operations: Note that the Technical Services segment was sold in 1999; ensure comparisons exclude these discontinued operations which generated significant gains in the prior year.
- Organic Growth: Validate the 12% organic growth rate cited by management against segment-specific performance data.